
How to include fibre in every meal? A nutritionist shares how she meets her daily quota with three meals
But here's the truth: Fibre is one of the most powerful tools for fat loss, hormone balance and fixing your gut. It's not just about digestion — it actually helps you feel full, reduces inflammation, supports insulin sensitivity (so important for PCOS, thyroid and diabetes) and even stabilises your moods.
The problem? We think we're eating enough fibre but we're not. Most of my clients think having two pieces of carrot or cucumber on their plate would be enough. But when I actually show them how much fibre they're missing, it's a big eye-opener.In most Indian urban diets, the average fibre intake is just 10–12 gm/day, while what your body actually needs daily is 15 gm per thousand calories. That amounts to 25 – 30 gm at least per day. And no, a spoon of salad on the side doesn't count.
Here's how I build fibre into my day without complicating my meals:
I keep it clean and local — no fancy stuff.
What I eat:
• 1 moong dal chila with lauki + green chutney → 4 – 5 gm fibre
• 1 seasonal fruit with skin (like guava or apple) → 3 – 4 gm fibre
• 1 tsp soaked chia or garden cress (halim) seeds in water → 4 gm fibre
Fibre from breakfast: 10 – 12 gm
No skipping sabzi here — it's the hero of the plate.
My go-to lunch:
• 2 phulkas (with ghee) → 3 gm
• 1 bowl bhindi or mixed veg sabzi → 4 gm
• 1 bowl rajma or dal → 6 – 7 gm
• Fresh kachumber salad → 3 gm
Fibre from lunch: ~15–16 gm
I keep dinner light but still rich in fibre — just more cooked, less raw (to avoid bloating).
Example dinner:
• Vegetable khichdi (rice+moong+lauki, carrots, peas) → 6 gm
• Stir-fried greens (like palak or methi) → 3 gm
• Beetroot curd or sautéed salad → 2 gm
Fibre from dinner: ~10–11 gm
Total Fibre for the Day: ~35–39 gm
And the best part? I'm not eating anything fancy or imported. Just real food. Cooked at home. With roti, rice, dal, sabzi, fruit and some smart add-ons like chia or salad.
• Don't skip vegetables. Make them 50 per cent of your lunch and dinner plate.
• Rotate your grains — try jowar, bajra, millets.
• Add one fruit (with skin!) and one bowl of salad daily.
• Sprinkle chia, flax or garden cress seeds in water, curd or smoothie.
• Use ghee — it helps fibre digest better and reduces bloating.
• And most importantly — don't fear fibre. Learn to work with it.
In case you have serious gut issues, make sure you talk to a gastroenterologist to optimise use.
(Batra is a nutritionist and fitness coach)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Gujarat ranks 3rd in sickle cell disease
Ahmedabad: Data tabled in the Lok Sabha on Aug 1 indicated that Gujarat, with 28,178 identified sickle cell disease patients, has the third-largest patient base in the country. Odisha, with 96,484 cases, leads the table, and is followed by Madhya Pradesh with 30,762 cases, according to data shared by Union health minister J P Nadda in response to a question by Rajkumar Raot. What set Gujarat apart was that 90% of the cases (25,282) were recorded among the scheduled tribes (ST), including those in the particularly vulnerable tribal group (PVTG) category, which was the highest among Indian states and significantly higher compared to Odisha and Madhya Pradesh, according to the statistics up to the end of July 2025. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad The answer indicated that a total of 77.34 lakh citizens were screened to identify those with the condition. Under the National Sickle Cell Anaemia Elimination Mission (NSCAEM), persons with the condition are provided counselling regarding lifestyle, pre-marriage and pre-natal decisions and nutritional supplements among others. "The condition is marked by abnormal haemoglobin that makes red blood cells rigid and take the shape of a sickle. They often block the blood flow, leading to anaemia," a public health expert said. "Gujarat has recently launched a drive to understand the genetic makeup of the tribal population," the expert added.
&w=3840&q=100)

Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.


Economic Times
3 hours ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'